Document is current

Article History

Received: 19 December 2024

Accepted: 3 July 2025

First Online: 13 July 2025

Declarations

:

: This study was conducted according to a protocol approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau (code IIBSP-NMI-2019–107) in accordance with the declaration of Helsinki. All patients provided written informed consent to participate in the study.

: Not applicable.

: L.Q. received research grants from UCB and Grifols; received speaker or expert testimony honoraria from CSL Behring, Novartis, Sanofi-Genzyme, Merck, Annexon, Alnylam, Biogen, Janssen, Lundbeck, ArgenX, UCB, LFB, Octapharma and Roche; serves at the Clinical Trial Steering Committee for Sanofi-Genzyme and Roche; and is Principal Investigator for UCB’s CIDP01 trial. J.P., M.C.M., A.P.C., A.H.D., J.G.F., S.I.Z. and M.R. are employed by Ephion Health, the company that provided the software and performed the analyses for this study. Ephion Health has commercial interest in the software used in this research. However, the Neuromuscular Diseases Unit maintained full control over the design, data collection, and interpretation of the clinical results. All other authors report no disclosures relevant to the manuscript.